Indaptus Therapeutics lost about $1.0 million last quarter, down from $3.0 million a year earlier.

Nov 13, 2026, 5:36 PM ETResultsRead the original at globenewswire.com

Neutral

Indaptus cut its loss, but research spending fell as clinical costs and payroll declined. Its cash and October financing support operations, but no study progress was reported, so the outlook is unchanged.

INDP · Indaptus Therapeutics

AI read · Neutral

The AI's read

Lower spending shrank the loss, but the report ties the research cut to lower study costs and payroll, not a better trial result. That leaves little evidence about the treatment's progress. The $30.6 million held at September's end, plus $24.0 million raised in October, gives the company more cash. The report shows cost savings and added funding, but no clear change in its research outlook.

Get alerts for INDP

Follow Indaptus Therapeutics (INDP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INDP

Free on the App Store and Google Play, or on the web.